Macrophage migration inhibitory factor predicts an unfavorable outcome after transarterial chemoembolization for hepatic malignancies

Transarterial chemoembolization (TACE) is a therapeutic option for patients with intermediate‐stage hepatocellular carcinoma (HCC) or metastatic liver cancers. Identifying those patients who particularly benefit from TACE remains challenging. Macrophage migration inhibitory factor (MIF) represents i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wirtz, Theresa H., Loosen, Sven H., Schulze‐Hagen, Max, Gorgulho, Joao, Kandler, Jennis, Joerdens, Markus, Demir, Münevver, Mohr, Raphael, Bruners, Philipp, Kuhl, Christiane, Trautwein, Christian, Berres, Marie‐Luise, Tacke, Frank, Luedde, Tom, Roderburg, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504849/
https://www.ncbi.nlm.nih.gov/pubmed/33787014
http://dx.doi.org/10.1111/cts.13033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504849/
https://www.ncbi.nlm.nih.gov/pubmed/33787014
http://dx.doi.org/10.1111/cts.13033

Ejemplares similares